Menu

Amyloid Designed to Inactivate Cancer-Related Protein

Researchers build a peptide that causes a receptor to form toxic, amyloid-like clumps in cells.

Nov 14, 2016
Kerry Grens

VEGFR2 bound by axitinibWIKIMEDIA, FUSE809Scientists have designed a peptide that homes in on an amyloid-vulnerable region of a protein involved in cancer, causing the molecule to aggregate and deactivate. The resulting protein clumps were toxic to cells—but only those that rely on the protein’s activity. The team published its findings in Science last week (November 11).

“Although we don’t yet know if functional amyloids could be used in humans for therapeutic applications, the potential for novel drugs is huge,” study coauthor Joost Schymkowitz of the University of Leuven, Belgium, said in a press release. “Our team will now spend the coming years trying to turn this into direct benefits for patients.”

With its designer peptide, called vascin, Schymkowitz’s group targeted vascular endothelial growth factor receptor (VEGFR2)—specifically, an “amyloidogenic sequence” within the protein. Although VEGFR2 doesn’t normally form amyloids, the designer peptide’s interaction with this vulnerable region caused VEGFR2 to snarl.

“We found vascin only to be toxic to cells that are dependent on VEGFR2 function, suggesting that toxicity is due to loss of VEGFR2 function and not to vascin aggregation or vascin-induced VEGFR2 aggregation,” Schymkowitz and his colleagues wrote in their report.

Speaking with STAT News, Schymkowitz said amyloid-inducing peptides could be deployed for combatting various diseases. “Because these principles apply to virtually any protein, our approach may not only be useful in developing future cancer therapies, but also in treating drug-resistant infections.” 

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Enabling Genomics-Guided Precision Medicine

Enabling Genomics-Guided Precision Medicine

Download this eBook from Qiagen to learn more about the promise of precision medicine and how QCITM Interpret can help deliver better care with better knowledge.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!